Short Interest in Lantheus Holdings, Inc. (NASDAQ:LNTH) Grows By 8.0%

Lantheus Holdings, Inc. (NASDAQ:LNTH) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,840,000 shares, an increase of 8.0% from the October 15th total of 4,480,000 shares. Based on an average daily volume of 988,100 shares, the days-to-cover ratio is currently 4.9 days. Currently, 7.2% of the shares of the company are sold short.

Insiders Place Their Bets

In other Lantheus news, President Paul Blanchfield sold 408 shares of the stock in a transaction on Monday, August 21st. The shares were sold at an average price of $66.10, for a total transaction of $26,968.80. Following the sale, the president now directly owns 90,067 shares of the company’s stock, valued at $5,953,428.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Paul Blanchfield sold 408 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $66.10, for a total transaction of $26,968.80. Following the completion of the transaction, the president now directly owns 90,067 shares in the company, valued at approximately $5,953,428.70. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Daniel Niedzwiecki sold 2,846 shares of Lantheus stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $66.43, for a total transaction of $189,059.78. Following the completion of the sale, the insider now owns 66,295 shares in the company, valued at $4,403,976.85. The disclosure for this sale can be found here. Insiders sold a total of 15,783 shares of company stock valued at $1,015,296 over the last 90 days. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Fairfield Bush & CO. purchased a new position in shares of Lantheus during the 1st quarter valued at $177,000. Raymond James & Associates purchased a new position in Lantheus in the first quarter valued at about $856,000. Bank of New York Mellon Corp increased its position in Lantheus by 2.7% in the 1st quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock worth $34,791,000 after purchasing an additional 16,422 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Lantheus by 14.4% during the 1st quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock worth $1,064,000 after purchasing an additional 2,427 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new stake in shares of Lantheus during the 1st quarter valued at about $354,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. TheStreet raised Lantheus from a “c” rating to a “b-” rating in a research note on Wednesday, August 9th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Monday, November 6th. Truist Financial restated a “buy” rating and set a $110.00 price objective on shares of Lantheus in a report on Wednesday, October 4th. Mizuho reiterated a “buy” rating and issued a $125.00 target price on shares of Lantheus in a report on Wednesday, October 4th. Finally, William Blair started coverage on shares of Lantheus in a report on Friday, September 29th. They set an “outperform” rating on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Lantheus currently has an average rating of “Buy” and an average price target of $115.00.

Lantheus Stock Down 0.3 %

Shares of LNTH traded down $0.18 during trading hours on Friday, reaching $67.97. The company’s stock had a trading volume of 270,287 shares, compared to its average volume of 1,014,503. The company has a 50 day moving average of $66.50 and a two-hundred day moving average of $77.35. The company has a quick ratio of 5.05, a current ratio of 5.37 and a debt-to-equity ratio of 0.80. The firm has a market cap of $4.66 billion, a price-to-earnings ratio of 47.66 and a beta of 0.66. Lantheus has a 1-year low of $47.46 and a 1-year high of $100.85.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.